2篇
您的检索式：作者名="Jason Gluck"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is Entresto good for the brain?显示文摘The main stay pharmacotherapy for heart failure(HF) is targeted towards rennin-angiotensin-aldosterone(RAAS) and neprilysin pathways(NP). Both therapeutic strategies decreases morbidity and mortality but also carry considerable adverse effects. This review of the literature highlights the new generation of HF drug, sacubitril-valsartan(SV), trade name Entresto(researched as LCZ696, Novartis) which simultaneously blocks RAAS and NP. This dual action of angiotensin receptors blocker and neprilysin inhibitor(NPi) has improved HF prognosis and it is an evolution in the management of HF. Although the initial follow-up of patients treated with SV has yielded promising results, there are concerns regarding potential side effects especially an increase in the risk of Alzheimer's disease(AD) and young onset of AD. NPi interferes with the breakdown and clearing of beta-amyloid peptides, the plaques seen in AD, raising concern for AD in SV patients. On the other hand, hypertension and cardiovascular diseases are established risk factors for AD which can be decreased by SV therapy. It is therefore essential that SV treated patients are followed up over an extended period of time to detect any adverse cognitive changes. | Nirav Patel Jason Gluck | 2017 | World Journal of Cardiology2017，9，7： | 2 |
| 2 | Review of heart transplantation from hepatitis C-positive donors显示文摘Significant scarcity of a donor pool exists for heart transplantation(HT)as the prevalence of patients with end-stage refractory heart failure is increasing exceptionally.With the discovery of effective direct-acting antiviral and favorable short-term outcomes following HT,the hearts from hepatitis C virus(HCV)patient are being utilized to increase the donor pool.Short-term outcomes with regards to graft function,coronary artery vasculopathy,and kidney and liver disease is comparable in HCV-negative recipients undergoing HT from HCVpositive donors compared to HCV-negative donors.A significant high incidence of donor-derived HCV transmission was observed with great success of achieving sustained viral response with the use of direct-acting antivirals.By accepting HCV-positive organs,the donor pool has expanded with younger donors,a shorter waitlist time,and a reduction in waitlist mortality.However,the longterm outcomes and impact of specific HCV genotypes remains to be seen.We reviewed the current literature on HT from HCV-positive donors. | Palak Patel Nirav Patel Fahad Ahmed Jason Gluck | 2022 | World Journal of Transplantation2022，12，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员